Anti-HER2 Cancer Therapy and Cardiotoxicity
Tania Babar, Christopher Blomberg, Eileen Hoffner and Xinhua Yan
Affiliation: Genesys Research Institute, Tufts University School of Medicine, 736 Cambridge St. CBR345, Boston, MA 02135.
A significant milestone in the treatment of breast cancer is the identification of the HER2 receptor as a drug target for cancer
therapies. Trastuzumab (Herceptin), a monoclonal antibody that blocks the HER2 receptor, is among the first of such drugs approved by
the US Food and Drug Administration for targeted cancer therapy. Clinical studies have shown that Trastuzumab significantly improves
the overall survival of breast cancer patients. However, an unforeseen significant side-effect of cardiotoxicity manifested as left ventricular
dysfunction and heart failure. Concurrent studies have demonstrated the essential role of the HER2 receptor in cardiac development
and maintaining the physiological function of an adult heart. The HER2 receptor, therefore, has become a critical link between the oncology
and cardiology fields. In addition to Trastuzumab, new drugs targeting the HER2 receptor, such as Lapatinib, Pertuzumab and
Afatinib, are either approved or being evaluated in clinical trials for cancer therapy. With the concern of cardiotoxicity caused by HER2
inhibition, it becomes clear that new therapeutic strategies for preventing such cardiac side effects need to be developed. It is the intent of
this paper to review the potential cardiac impact of anti-HER2 cancer therapy.
Keywords: HER2, cardiotoxicity, cancer, therapy.
Rights & PermissionsPrintExport